Envision Pharma Group
PHILADELPHIA, PA / ACCESSWIRE / May 4, 2023 / Envision Pharma Group (Envision) has appointed Dr. Jennifer Costello, PharmD, BCPS, CMPP, to the role of Chief Medical Officer. Jennifer will be responsible for progressing work across all sectors of Envision's business, including Technology, Medical, Commercial, Public Affairs, and Value & Access and Data Analytics.
Meg Heim, CEO of Envision Pharma Group, adds, "I am so excited to welcome Jennifer to the Envision team as Chief Medical Officer. Jennifer's deep expertise in science and commercialization in the life sciences industry, in addition to her extensive pharmaceutical understanding and experience will further support the acceleration of our business expansion, mission, and commitment to our vision as a technology-enabled partner to the life sciences industry."
Jennifer is an accomplished pharmaceutical and healthcare leader with over 20 years of experience across the healthcare sector. She brings to this role extensive cardiovascular, medical, and patient care-related focused expertise, with a successful track record of leading high-performing cross-matrix teams with global impact.
Prior to joining Envision, Jennifer held multiple leadership roles in global medical affairs and publications, US HEOR publications, and global scientific content. She developed a reputation for leading successful partnerships with cross-functional colleagues, advocacy partners, and academic groups that resulted in building innovative programs that foster healthcare transformation.
Jennifer joins Envision from Bristol Myers Squibb, where she most recently led cardiovascular (CV) patient advocacy across its CV portfolio (early phase assets to marketed products). She drove the development and execution of global and US strategies for a successful launch of a first-in-class CV asset, working across early asset development, commercial, and medical affairs teams. For her work in this space, she was awarded the coveted "Innovation Award" from BMS.
Before joining the pharmaceutical industry, her 16 years of experience as a practicing clinical pharmacist was within the academic medical-teaching hospital. Jennifer served in numerous roles as a pediatric critical care specialist, adult ambulatory clinical care specialist, hospital administrator, and as a Director of Clinical Pharmacy Services. Under a collaborative practice agreement, she also led outpatient care optimization, directly co-managing heart failure, antithrombotic, and diabetic patients.
Jennifer received her PharmD from Northeastern University, completed her ASHP PGY-1 residency at the University of Arizona/University Medical Center, and received her board certification as a pharmacotherapy specialist from the American College of Clinical Pharmacy. She served in adjunct teaching positions with Rutgers University and the University of Florida. She has authored over 50 publications and posters and served as a pharmacy national thought leader within the heart failure, antithrombotic, and diabetes management space.
Jennifer adds, "I am delighted and humbled to join the Envision team during this transformative time. I am looking forward to meeting and working with our Envision family, customers, and partners. This is an exciting period for our industry at large, and I am privileged to build upon our company vision, award-winning technology, and innovation as medical affairs and global healthcare communication leaders."
About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.
Contact Information
Colleen Carter
Associate Director, Communications, Office of the CEO
colleen.carter@envisionpharma.com
1 (508) 505 8856
SOURCE: Envision Pharma Group
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/752444/Envision-Pharma-Group-Appoints-Healthcare-Industry-Expert-and-Experienced-Leader-Dr-Jennifer-Costello-PharmD-BCPS-CMPP-as-Chief-Medical-Officer
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Rust Mobile Revealed With Official Trailer, First Hands-on Demo Set for Gamescom 20251.8.2025 18:30:00 CEST | Press release
The new cinematic trailer showcases Rust Mobile retaining the DNA of its PC predecessor, from cutthroat PvP to base raiding while offering the accessibility and flexibility of mobile Players can get a hands-on experience of Rust Mobile as it makes its debut at gamescom from 20th to 24th August Players are invited to pre-register at rustmobile.com SHENZHEN, CN / ACCESS Newswire / August 1, 2025 / Level Infinite is thrilled to reveal gameplay features for Rust Mobile, the officially licensed mobile adaptation of the iconic PC survival game Rust. Recreating the brutal survival experience, Rust Mobile combines the original with mobile-first innovations and will see its public hands-on debut at gamescom 2025.Rust Mobile Revealed Pre-registration is open now Watch the cinematic trailer here. Officially licensed by Facepunch Studios, Rust Mobile stays true to the uncompromising spirit of the original, delivering a survival experience fans know and love. From open-world exploration and ruthles
Innodata Reports Second Quarter 2025 Results with Revenue up 79% Year-Over-Year and Raises Full Year Guidance31.7.2025 22:15:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / July 31, 2025 / INNODATA INC. (Nasdaq:INOD) today reported results for the second quarter ended June 30, 2025. Revenue of $58.4 million, representing 79% year-over-year organic revenue growth. Adjusted EBITDA of $13.2 million, an increase of $10.4 million from $2.8 million in the same period last year.* Net income of $7.2 million, or $0.23 per basic share and $0.20 per diluted share, compared to a de minimis net loss, or $0.00 per basic and diluted share, in the same period last year. Cash, cash equivalents and short-term investments were $59.8 million as of June 30, 2025 and $46.9 million as of December 31, 2024. * Adjusted EBITDA is defined below. Jack Abuhoff, CEO, said, "Q2 was another outstanding quarter. We beat analysts' expectations across the board on key metrics - revenue, Adjusted EBITDA, net income, and fully-diluted EPS. As a result of strong demand and momentum, which includes significant new deal wins across a diversity of new and existin
Polaris Renewable Energy Announces Q2 2025 Results31.7.2025 14:00:00 CEST | Press release
TORONTO, ONTARIO / ACCESS Newswire / July 31, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the three and six months ended June 30, 2025. This earnings release should be read in conjunction with the Company's condensed consolidated interim financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. 2025 HIGHLIGHTS Second quarter consolidated energy production totaled 215,797 MWh, representing a 15% increase compared to 186,886 MWh in the same quarter last year. The increase is mainly attributable to stronger hydrological conditions in Peru and the contribution from the Puerto Rican wind farm, acquired on March 3, 2025, which did not contribute to consolidated energy production in t
Polaris Renewable Energy Declares Quarterly Dividend31.7.2025 14:00:00 CEST | Press release
TORONTO, ONTARIO / ACCESS Newswire / July 31, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on August 22nd to shareholders of record at the close of business on August 11th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Company's ope
New Report Reveals Key Considerations For Successful Distribution Onboarding30.7.2025 15:00:00 CEST | Press release
NASHVILLE, TN / ACCESS Newswire / July 30, 2025 / The Global Technology Distribution Council (GTDC) released its collaborative research report titled "The Distribution Onramp: A Quick-Start Guide for Established and Emerging Technology Vendors" during the GTIA ChannelCon event this week. The engaging new study provides valuable best practices for initiating and developing strong and mutually beneficial relationships between technology suppliers and distributors. In today's fast-paced technology landscape, IT vendors are under immense pressure to scale their sales, technical support and other operations quickly and efficiently to meet market demands and stay ahead of the competition. GTDC's latest report illustrates how a well-designed channel program can create an accelerated path to achieving these goals, particularly if the organization leverages two-tier distribution to cost-effectively expand their reach, enhance customer engagement and drive net new sales. This valuable industry r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom